Skip to main content
30/06/2022

A VHIR study on the symptoms of persistent COVID funded by the Fundación Mutua Madrileña

Alegre-Covid-Persistent-FMM
Mutua_Madrileña_Jose_Alegre_COVID

30/06/2022

The research led by Dr. José Alegre has been one of the 21 projects selected in the 19th call for Health Research Grants.

A clinical study, led by Dr. José Alegre, coordinator of the Chronic Fatigue Syndrome Unit of the Vall d'Hebron University Hospital and principal investigator of the Rheumatology group of the Vall d'Hebron Research Institute (VHIR), that aims to deepen the knowledge of the persistent COVID-19 will be funded by the Mutua Madrileña Foundation. It has been one of the 21 projects selected in the XIX Foundation’s Health Research Grants, which allocated two million euros to this call.

The goal of the study will be to characterize the main symptoms that SARS-CoV-2 leaves in some people who suffer from the disease, such as disabling chronic morning fatigue (post-exertional fatigue), memory/concentration disturbances, non-refreshing sleep, orthostatic intolerance. It is the called Persistent Covid, a chronic fatigue syndrome after SARS-CoV2 infection. "This condition is a chronic disabling process that causes severe impairment of functional capacity and quality of life, both at work and in the personal and social spheres, so it is urgent to have personalized therapeutic targets for the development of effective drugs that modify the evolution of the process towards chronicity," explains Dr. Alegre. "SARS-CoV-2-induced chronic fatigue syndrome is an excellent clinical and experimental model of post-viral syndromes, useful to understand the neurobiological mechanisms involved in chronic fatigue after infectious processes," he adds.

Dr. Alegre took part in the award ceremony for the Health Research Grants held in Madrid on Wednesday, June the 29th. The ceremony was presided over by the Minister of Health of the Community of Madrid, Enrique Ruiz Escudero, the president of the Mutua Group and its foundation, Ignacio Garralda, and the president of the Scientific Committee of the Fundación Mutua Madrileña, Dr. Rafael Matesanz. With these grants, the Mutua Foundation contributes financially to the high quality medical research carried out in Spain. In total, taking into account all the hospitals that will participate in the collaborative projects, the Mutua Foundation will support the research teams of 19 hospitals. From Barcelona, there were also recognized two IDIBAPS studies focused on rare diseases and transplants. In addition, four Catalan teams from Vall d'Hebron and IDIBAPS are participating in other collaborative projects led by other hospitals in Spain, in the areas of rare diseases in children and lung cancer, which have also been awarded funding.
 

The goal of the study will be to characterize the main symptoms that SARS-CoV-2 leaves in some people.

Related news

The head of the Rheumatology Service at Vall d'Hebron University Hospital and of the Rheumatology research group at VHIR is a highly accomplished rheumatologist with a distinguished career in the field.

It is the first international multi-centre clinical trial to analyse the safety and effect of this treatment for an autoimmune disease.

Els estudis avançaran en els camps de les malalties digestives, el VIH, la fatiga crònica, les patologies cardíaques, l’hepatitis, la diabetis i l’oftalmologia.

Related professionals

Alcaraz Lopez, Carlos Jorge

Alcaraz Lopez, Carlos Jorge

Rheumatology
Read more
Elena Granell  Pallares

Elena Granell Pallares

Administration and Management
Rheumatology
Read more
Sanchez Encinales, Viviana

Sanchez Encinales, Viviana

Research technician
Rheumatology
Read more
Mariona Colom Saborit

Mariona Colom Saborit

Research technician
Rheumatology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.